Next Article in Journal
Helical-Ribbon and Tape Formation of Lipid Packaged [Ru(bpy)3]2+ Complexes in Organic Media
Next Article in Special Issue
Expression of HERV Genes as Possible Biomarker and Target in Neurodegenerative Diseases
Previous Article in Journal
Adipose-Derived Stem Cells in Cancer Progression: New Perspectives and Opportunities
Previous Article in Special Issue
MCEE Mutations in an Adult Patient with Parkinson’s Disease, Dementia, Stroke and Elevated Levels of Methylmalonic Acid
Open AccessReview

Lessons on Differential Neuronal-Death-Vulnerability from Familial Cases of Parkinson’s and Alzheimer’s Diseases

1
Chemistry School, University of Barcelona, 08028 Barcelona, Spain
2
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CiberNed), Instituto de Salud Carlos III, 28031 Madrid, Spain
3
Department of Biochemistry and Physiology, Faculty of Pharmacy, University of Barcelona, 02028 Barcelona, Spain
4
Departamento de Morfología y Biología Celular, Facultad de Medicina, Universidad de Oviedo, 33006 Oviedo, Spain
5
Instituto de Neurociencias del Principado de Asturias (INEUROPA), 33003 Oviedo, Asturias, Spain
6
Instituto de Salud del Principado de Asturias (ISPA), 33011 Oviedo, Asturias, Spain
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(13), 3297; https://doi.org/10.3390/ijms20133297
Received: 4 June 2019 / Revised: 28 June 2019 / Accepted: 2 July 2019 / Published: 4 July 2019
The main risk of Alzheimer’s disease (AD) and Parkinson’s disease (PD), the two most common neurodegenerative pathologies, is aging. In contrast to sporadic cases, whose symptoms appear at >60 years of age, familial PD or familial AD affects younger individuals. Finding early biological markers of these diseases as well as efficacious treatments for both symptom relief and delaying disease progression are of paramount relevance. Familial early-onset PD/AD are due to genetic factors, sometimes a single mutation in a given gene. Both diseases have neuronal loss and abnormal accumulations of specific proteins in common, but in different brain regions. Despite shared features, the mechanisms underlying the pathophysiological processes are not known. This review aims at finding, among the genetic-associated cases of PD and AD, common trends that could be of interest to discover reliable biomarkers and efficacious therapies, especially those aimed at affording neuroprotection, i.e., the prevention of neuronal death. View Full-Text
Keywords: glucocerebrosidase; maternal imprinting; mitochondria; steryl glycosides; cholesterol glucocerebrosidase; maternal imprinting; mitochondria; steryl glycosides; cholesterol
Show Figures

Figure 1

MDPI and ACS Style

Franco, R.; Navarro, G.; Martínez-Pinilla, E. Lessons on Differential Neuronal-Death-Vulnerability from Familial Cases of Parkinson’s and Alzheimer’s Diseases. Int. J. Mol. Sci. 2019, 20, 3297.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop